Search research articles
Contact Us
Filters
Showing results (61-70 of 110) with videos related to
Page
of 11
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
November 22, 2013
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer
Olivier Humbert, Alina Berriolo-Riedinger, Alexandre Cochet, et al.
The Oncologist
|
December 23, 2018
Long-Term Gynecological Cancer Survivors in Côte d'Or: Health-Related Quality of Life and Living Conditions
Ariane Mamguem Kamga, Agnès Dumas, Florence Joly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
José Baselga, Karen A Gelmon, Shailendra Verma, et al.
Breast (Edinburgh, Scotland)
|
June 19, 2018
Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab
Quentin Jacquinot, Sophie Paget-Bailly, Pierre Fumoleau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors
Godefridus J Peters, Paul Noordhuis, Cornelis J Van Groeningen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 21, 2014
HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy
Olivier Humbert, Alexandre Cochet, Jean-Marc Riedinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 21, 2012
Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors
Alexandre Cochet, Sophie Pigeonnat, Blandine Khoury, et al.
The Journal of Pathology
|
March 26, 2011
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Sylvain Ladoire, Grégoire Mignot, Sandrine Dabakuyo, et al.
American Journal of Clinical Oncology
|
June 3, 2009
Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy
Pierre Fumoleau, Hernan Cortés-Funes, Amina B Taleb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2004
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
Véronique Diéras, Pierre Fumoleau, Gilles Romieu, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 110) with videos related to
Sort By:
Page
of 11
European Journal of Nuclear Medicine and Molecular Imaging
|
November 22, 2013
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer
Olivier Humbert, Alina Berriolo-Riedinger, Alexandre Cochet, et al.
The Oncologist
|
December 23, 2018
Long-Term Gynecological Cancer Survivors in Côte d'Or: Health-Related Quality of Life and Living Conditions
Ariane Mamguem Kamga, Agnès Dumas, Florence Joly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
José Baselga, Karen A Gelmon, Shailendra Verma, et al.
Breast (Edinburgh, Scotland)
|
June 19, 2018
Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab
Quentin Jacquinot, Sophie Paget-Bailly, Pierre Fumoleau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors
Godefridus J Peters, Paul Noordhuis, Cornelis J Van Groeningen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 21, 2014
HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy
Olivier Humbert, Alexandre Cochet, Jean-Marc Riedinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 21, 2012
Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors
Alexandre Cochet, Sophie Pigeonnat, Blandine Khoury, et al.
The Journal of Pathology
|
March 26, 2011
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Sylvain Ladoire, Grégoire Mignot, Sandrine Dabakuyo, et al.
American Journal of Clinical Oncology
|
June 3, 2009
Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy
Pierre Fumoleau, Hernan Cortés-Funes, Amina B Taleb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2004
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
Véronique Diéras, Pierre Fumoleau, Gilles Romieu, et al.
Page
of 11